Clinical, neuroimaging, and molecular spectrum of TECPR2-associated hereditary sensory and autonomic neuropathy with intellectual disability

Sonja Neuser*, Barbara Brechmann, Gali Heimer, Ines Brösse, Susanna Schubert, Lauren O'Grady, Michael Zech, Siddharth Srivastava, David A. Sweetser, Yasemin Dincer, Volker Mall, Juliane Winkelmann, Christian Behrends, Basil T. Darras, Robert J. Graham, Parul Jayakar, Barry Byrne, Bat El Bar-Aluma, Yael Haberman, Amir SzeinbergHesham M. Aldhalaan, Mais Hashem, Amal Al Tenaiji, Omar Ismayl, Asma E. Al Nuaimi, Karima Maher, Shahnaz Ibrahim, Fatima Khan, Henry Houlden, Vijayalakshmi S. Ramakumaran, Alistair T. Pagnamenta, Jennifer E. Posey, James R. Lupski, Wen Hann Tan, Gehad ElGhazali, Isabella Herman, Tatiana Muñoz, Gabriela M. Repetto, Angelika Seitz, Mandy Krumbiegel, Maria Cecilia Poli, Usha Kini, Stephanie Efthymiou, Jens Meiler, Reza Maroofian, Fowzan S. Alkuraya, Rami Abou Jamra, Bernt Popp, Bruria Ben-Zeev, Darius Ebrahimi-Fakhari

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

Bi-allelic TECPR2 variants have been associated with a complex syndrome with features of both a neurodevelopmental and neurodegenerative disorder. Here, we provide a comprehensive clinical description and variant interpretation framework for this genetic locus. Through international collaboration, we identified 17 individuals from 15 families with bi-allelic TECPR2-variants. We systemically reviewed clinical and molecular data from this cohort and 11 cases previously reported. Phenotypes were standardized using Human Phenotype Ontology terms. A cross-sectional analysis revealed global developmental delay/intellectual disability, muscular hypotonia, ataxia, hyporeflexia, respiratory infections, and central/nocturnal hypopnea as core manifestations. A review of brain magnetic resonance imaging scans demonstrated a thin corpus callosum in 52%. We evaluated 17 distinct variants. Missense variants in TECPR2 are predominantly located in the N- and C-terminal regions containing β-propeller repeats. Despite constituting nearly half of disease-associated TECPR2 variants, classifying missense variants as (likely) pathogenic according to ACMG criteria remains challenging. We estimate a pathogenic variant carrier frequency of 1/1221 in the general and 1/155 in the Jewish Ashkenazi populations. Based on clinical, neuroimaging, and genetic data, we provide recommendations for variant reporting, clinical assessment, and surveillance/treatment of individuals with TECPR2-associated disorder. This sets the stage for future prospective natural history studies.

Original languageEnglish
Pages (from-to)762-776
Number of pages15
JournalHuman Mutation
Volume42
Issue number6
DOIs
StatePublished - Jun 2021

Funding

FundersFunder number
Astellas Pharmaceutical Inc.
CureAP4 Foundation
CureSPG50 Foundation
Exome Aggregation Consortium
MitoBridge Inc
National Health Service
National Heart, Lung, and Blood InstituteK08 HG008986
National Human Genome Research InstituteUM1HG006542
Thrasher Research Fund
Wellcome Trust
Heart of England NHS Foundation Trust
Baylor-Hopkins Center for Mendelian Genomics
Bayer Foundation
Spastic Paraplegia Foundation
Medical Research Council
National Institute for Health Research
Department of Health and Social Care
Cancer Research UK
Deutsche ForschungsgemeinschaftPO2366/2–1
Studienstiftung des Deutschen Volkes

    Keywords

    • Human Phenotype Ontology
    • TECPR2
    • neurodevelopmental disorder
    • sensory autonomic neuropathy
    • spastic paraplegia

    Fingerprint

    Dive into the research topics of 'Clinical, neuroimaging, and molecular spectrum of TECPR2-associated hereditary sensory and autonomic neuropathy with intellectual disability'. Together they form a unique fingerprint.

    Cite this